First non-immunosuppressive dual-action therapy recommended by NICE for eligible patients with IgA nephropathy, a leading ...

CSL Behring’s new facility in Broadmeadows, Victoria, has been named the 2025 Facility of the Year by the International Society for Pharmaceutical Engineering (ISPE), in the Pharma 4.0 category. The ...